Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
Résumé
Tralokinumab, an anti‐interleukin‐13 biologic for the treatment of atopic dermatitis (AD), has provided significant and early improvements in signs and extent of AD in key Phase 3 clinical trials and was well tolerated, with a safety profile comparable to placebo. This study comprehensively assessed the safety profile of tralokinumab using data from five placebo‐controlled trials in adult patients with moderate‐to‐severe AD, finding that overall incidence and rate of adverse events (AEs) was similar between tralokinumab and placebo in the initial treatment period (16 weeks) and did not increase over 52 weeks of continued treatment. Common AEs occurring more frequently with tralokinumab included conjunctivitis and injection site reaction.
Domaines
Sciences du Vivant [q-bio]Origine | Publication financée par une institution |
---|---|
Licence |